Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

Key Inclusion Criteria:

• Documented evidence of recurrent/persistent endometrial cancer (endometrialcarcinoma or carcinosarcoma).

• Up to 3 prior lines of systemic therapy for endometrial cancer, including systemicplatinum-based chemotherapy and anti-PD-1/PD-L1 therapy, either in combination orseparately.

• Eligible for treatment with either doxorubicin or paclitaxel as determined by theinvestigator.

• Radiologically evaluable disease (either measurable or nonmeasurable) by computedtomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1.

• Eastern Cooperative Oncology Group performance status score of 0 or 1.

• Adequate organ function

Key Exclusion Criteria:

• Uterine leiomyosarcoma and endometrial stromal sarcomas are excluded.

• Participants who are candidates for curative-intent therapy at the time of studyenrollment.

• Participants eligible for rechallenge with platinum-based chemotherapy as determinedby the investigator.

• Received any prior treatment with a Trop-2-directed antibody-drug conjugate (ADC).

• Have an active second malignancy.

• Have an active serious infection requiring systemic antimicrobial therapy.

• Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease)or gastrointestinal perforation within 6 months prior to randomization.

• Have a positive serum pregnancy test or are breastfeeding for participants who areassigned female at birth.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.